Grifols SA ADR
Yahoo Finance • 13 days ago
Grifols, S.A. (GRFS) to Double Plasma Production With New Spain Facility
In this article, we will be taking a look at the 7 Hot Healthcare Stocks to Buy Right Now. Grifols, S.A. is one of them. Grifols, S.A. (NASDAQ:GRFS) tops our list for being one of the hot stocks to buy. It is headquartered in Barcelona an... Full story
Yahoo Finance • last month
GRIFOLS SA-ADR (NASDAQ:GRFS) Screens as High-Growth Momentum Stock with Strong Technicals
GRIFOLS SA-ADR (NASDAQ:GRFS [https://www.chartmill.com/stock/quote/GRFS]) has recently appeared through a screening process that joins Mark Minervini’s Trend Template with a High Growth Momentum (HGM) rating. This two-part method finds sto... Full story
Yahoo Finance • last month
BTS and clients recognized with 59 Brandon Hall Group Excellence Awards in 2025
SAN FRANCISCO, August 20, 2025--(BUSINESS WIRE)--BTS GROUP AB (publ), a global leader in strategy implementation, has earned 59 Brandon Hall Group Excellence Awards in 2025 alongside its clients. These awards recognize some of BTS’s most i... Full story
Yahoo Finance • 2 months ago
Grifols S.A. declares $0.1404 dividend
* Grifols S.A. (NASDAQ:GRFS [https://seekingalpha.com/symbol/GRFS]) declares $0.1404/share dividend. * Forward yield [https://seekingalpha.com/symbol/GRFS/dividends/yield?source=news_bullet] 5.25% * Payable Aug. 20; for shareholders... Full story
Yahoo Finance • 2 months ago
Grifols ADR earnings beat, revenue fell short of estimates
Investing.com - Grifols ADR (NASDAQ: GRFS) reported second quarter EPS of $0.23, better than the analyst estimate of $0.22. Revenue for the quarter came in at $2.18B versus the consensus estimate of $2.2B. Grifols ADR’s stock price closed... Full story
Yahoo Finance • 2 months ago
Astrazeneca, Other US-Listed Pharma Companies Seen Insulated From New EU Tariff Deal, Barclays Says
Astrazeneca (AZN), Grifols (GRFS), and Argenx (ARGX) appear to be the least exposed to tariffs and l PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 4 months ago
Grifols lawsuit against Gotham City to proceed after New York court ruling
[satin flags with letters GRIFOLS fluttering on silk cloth, global healthcare company develops plasma-derived medicines, innovative biopharmaceutical solutions, Frankfurt, Germany - February 13, 2024] Victor Golmer/iStock Editorial via Get... Full story
Yahoo Finance • 4 months ago
Grifols reports Q1 adjusted EBITDA of EUR 400M, up 14.2% from last year
Net revenues reached EUR 1.786B, up 7.4% in constant currency. Like-for-like net revenues increased by 10.0% in constant currency. Adjusted EBITDA increased to EUR 400M, up 14.2% in constant currency and +21.7% on a constant currency, like... Full story
Yahoo Finance • 4 months ago
Grifols reaffirms guidance for 2025
Grifols (GRFS) said: “Grifols remains focused on the continued execution of its strategic plan and reaffirms its guidance for FY2025. Due to the impact of the Inflation Reduction Act on its financial results, Grifols expects to share great... Full story
Yahoo Finance • 12 months ago
GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
GigaGen, Inc. The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen’s recombinant polyclonals are p... Full story
Yahoo Finance • last year
Grifols 2023 Annual Report on Form 20-F filed with the SEC
BARCELONA, Spain, April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Rep... Full story
Yahoo Finance • 2 years ago
Charles Brandes Bolsters Portfolio with a Strategic Emphasis on Corteva Inc
Insight into the Investment Moves of a Value Investing Stalwart Charles Brandes (Trades, Portfolio), a seasoned value investor and founder of Brandes Investment Partners, has made notable changes to his investment portfolio in the fourth... Full story
Yahoo Finance • 2 years ago
Grifols Sues in NY Over Gotham City Short-Seller Report
(Bloomberg) -- Grifols SA sued Gotham City Research over a report alleging the company has overstated profit and misstated its accounting. Most Read from Bloomberg Putin Sends US Signal on Ukraine Talks, Seeing War Advantage One of World... Full story
Yahoo Finance • 2 years ago
Grifols sees no impact from Gotham report on China stake sale
BARCELONA (Reuters) -Spanish pharma company Grifols sees no problem closing the sale of a stake in Shanghai RAAS despite the market impact of a negative report by Gotham City Research that questioned its accounting, which Grifols top brass... Full story
Yahoo Finance • 2 years ago
Factbox-What does the Gotham City report say about Grifols?
By Nell Mackenzie LONDON (Reuters) - Shares in Grifols fell as much as over 40% on Tuesday, wiping $3.83 billion off its market value, after hedge fund Gotham City Research questioned its accounting, prompting the Spanish drugmaker to "ca... Full story
Yahoo Finance • 2 years ago
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
Grifols, S.A. Study designed to demonstrate impact of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), an alpha1 antitrypsin treatment, compared with Liquid Alpha1-Proteinase Inhibitor (Human) intravenous This first in... Full story
Yahoo Finance • 2 years ago
GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023
Researchers from the National Cancer Institute will conduct the Phase 1 trial, as established in a recently signed Cooperative Research and Development Agreement (CRADA) GigaGen anticipates trial initiation in 2024 GIGA-564 is a differen... Full story
Yahoo Finance • 2 years ago
Grifols, S.A. (NASDAQ:GRFS) Q3 2023 Earnings Call Transcript
Grifols, S.A. (NASDAQ:GRFS) Q3 2023 Earnings Call Transcript November 2, 2023 Nuria Pascual: Hello, everyone, and welcome to the Grifols Third Quarter 2023 Conference Call. Thank you very much for taking the time to join us today. This is... Full story
Yahoo Finance • 2 years ago
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
Trial met primary endpoints, confirming vaccine’s safety, tolerability and robust immune response against the Aβ40 peptide in early-stage Alzheimer's patientsABvac40 treatment slowed disease progression up to 38% compared with placebo as m... Full story
Yahoo Finance • 2 years ago
GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary... Full story
